Joshua Fitch is the senior editor for Contemporary Pediatrics. He joined the brand in March of 2023 as an editor before being promoted to senior editor in January 2024. Fitch graduated from Youngstown ...

As summer approaches, pediatric dermatologist John Browning, MD, Chief of Dermatology at Children’s Hospital of San Antonio is reminding families to stay vigilant about sun safety, especially for ...

The FDA has extended its review of Incyte’s supplemental New Drug Application (sNDA) for ruxolitinib cream 0.75% (Opzelura) for the treatment of mild to moderate atopic dermatitis (AD) in children ...

The FDA’s June 9, 2025, approval of clesrovimab (Enflonsia; Merck) to prevent respiratory syncytial virus (RSV) in infants could have potential ripple effects of RSV prevention—not only in reducing ...

Researchers at Rutgers Health have proposed a new approach to addressing Sudden Unexpected Infant Death (SUID)—caffeine. In a hypothesis published in the Journal of Perinatology, they suggest caffeine ...

Michael O. Daines, MD, division chief of Pediatric Allergy and Immunology at the University of Arizona College of Medicine and principal investigator of the phase 3 trial evaluating Panzyga for ...

Addictive use of screens—not total time—was linked to higher risks of suicidal behavior and mental health issues in early adolescents. A large cohort study published in JAMA has found that both high ...

John Browning, MD, highlights why pediatricians should feel comfortable prescribing recent non-steroidals, and what questions to ask patients in office. John Browning, MD, Chief of Dermatology at ...

The nearly 4000 cases in 2023 were the highest number reported in over 30 years, the Task Force stated ...

On June 18, Biogen announced the dosing of participants in the BRAVE study (NCT06953583), a global phase 3 clinical trial evaluating omaveloxolone (Skyclarys) in children aged 2 to younger than 16 ...

Case A previously healthy 10-year-old female presented to the primary care pediatric office with complaints of new onset headaches that were localized to the left side of her forehead and the left ...

On June 18, 2025, the FDA approved Gilead Sciences' lenacapavir (Yeztugo), an injectable HIV-1 capsid inhibitor, indicated as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired ...